601A
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 27, 2025
601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
(clinicaltrials.gov)
- P2 | N=60 | Completed | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion
June 27, 2025
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
(clinicaltrials.gov)
- P2 | N=60 | Completed | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion
January 13, 2023
A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
(clinicaltrials.gov)
- P3 | N=350 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2025 ➔ Dec 2025 | Initiation date: Sep 2022 ➔ Dec 2022 | Trial primary completion date: Jun 2025 ➔ Dec 2025
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion
August 29, 2022
A Phase III Study for 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
(clinicaltrials.gov)
- P3 | N=350 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
New P3 trial • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion
1 to 4
Of
4
Go to page
1